Incidence and characteristics of adverse drug reactions in a cohort of patients treated with PD-1/PD-L1 inhibitors in real-world practice.

ABSTRACT:

Background

Data related to adverse drug reactions (ADRs), specifically immune-related adverse events (irAEs), in long-term treatment with immunotherapy in real-world practice is scarce, as is general information regarding the management of ADRs.

Objectives

To characterize and describe the incidence of ADRs in patients who began immunotherapy treatment in clinical practice.

Methods

In a prospective observational study cancer patients ≥18 years of age who were treated with a monotherapy regime of PD-1/PD-L1 inhibitors were evaluated. The study period was from November 2017 to June 2019 and patients were followed up until June 2021. Patients were contacted monthly by telephone and their electronic health records were reviewed. Each ADR was graded according to the Common

SUBMITTER: Sabate Gallego M 

PROVIDER: S-EPMC9441693 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature